OR WAIT 15 SECS
Kieran O’Connor is Analytical Science and Technology senior chemist at SK biotek, Ireland, email@example.com. (formerly Bristol Myers Squibb)
John Wasylyk is senior principal scientist at Bristol-Myers Squibb, USA; firstname.lastname@example.org
Bob Wethman is senior research scientist II at Bristol-Myers Squibb, USA
Ming Huang is senior research investigator I at Bristol-Myers Squibb, USA
Spectroscopic-based control methods were introduced as equivalent alternative methods, first to a gas chromatographic method to monitor an in-process solvent exchange step and second to a potentiometric titration method to release a process input material for drug substance manufacturing.
Submitted: Sept. 28, 2018. Accepted: Oct. 16, 2018.
The biopharmaceutical industry is responding to the need for accelerated development timelines of new medicines and identifying opportunities to accelerate development and optimize the manufacturing process. Spectroscopic-based controls have been demonstrated to be quicker, more flexible, and easier to operate and automate than traditional analytical control applications. This paper describes two separate case studies in which spectroscopic methods were introduced as equivalent alternative methods, first to a gas chromatographic method to monitor an in-process solvent exchange step and second to a potentiometric titration method to release a process input material. The spectroscopic techniques implemented were Raman and Fourier transform near infrared (FT-NIR) spectroscopy. The implementation of the spectroscopic methods generated significant increases in sample throughput as well as reductions in plant cycle time, analysis times, and incidences of analytical deviations.
The Food and Drug Administration (FDA) Safety and Innovation Act of 2012 (1) established a breakthrough designation program to expedite the development and approval of innovative drugs for serious and life-threatening conditions. As biopharmaceutical companies have identified the potential to file new drug entities as breakthrough designation candidates, they need to concurrently identify opportunities and strategies that will allow them to accelerate the development process and optimize manufacturing. FDA and other regulatory authorities are encouraging the industry to adopt a more risk-based, scientific approach to drug development and manufacture, as detailed in the FDA Guidance for Industry document Process Validation: General Principles and Practices (2) and the International Council for Harmonization (ICH) Q8, Q9, Q10, and Q11 documents (3–6). These documents detail techniques, procedures, and strategies by which increased process knowledge and understanding, and ultimately greater process control, are obtained. These advances are accomplished through comprehensive development activities, including creation of a process design space, thorough and challenging risk assessments, and use of process analytical technologies (PAT) to develop critical process parameters (CPP) for control. The knowledge obtained through these approaches can subsequently be applied to risk-based decisions to accelerate the development process.
Bristol-Myers Squibb (BMS) actively embraces this risk-based approach to drug development and manufacture and has established PAT-focused research groups within both drug substance and drug product development to enable robust data generation and process understanding. The Enabling Technologies Group (ETG), within the Chemical and Synthetics Development department, specializes in the development and implementation of spectroscopic-based methods for process monitoring of pharmaceutical and biopharmaceutical drug substance development and manufacture. The ETG collaborated with BMS Ireland’s small-molecule drug substance commercial manufacturing site (which changed ownership to become SK biotek Ireland in January 2018) to identify opportunities to introduce spectroscopic-based methods of analysis to generate richer batch data sets and increase the overall efficiency of the site manufacturing operations.
One unit operation that was quickly identified as an opportunity to increase the efficiency of both the plant cycle time and the quality control (QC) laboratory was the monitoring of solvent “swaps” or exchanges in the reactors. Solvent exchange is one of the most common unit operations in a drug substance manufacturing facility, as solvents routinely need to be removed for multiple reasons, such as for compatibility with subsequent reaction steps, to facilitate crystallization, and/or to purge impurities. The team evaluated the solvent exchanges used in the production of the high-volume products that the site manufactured for opportunities to implement spectroscopic-based methods. These opportunities would afford the greatest gains in plant and laboratory efficiency. The target identified was an in-process solvent exchange step that employed gas chromatography (GC) as an in-process control (IPC) test. The overall impact to the plant cycle time was significant, as the reactor needed to be cooled to a safe temperature before a sample could be taken and transferred to the QC laboratory where the sample analysis and data processing takes approximately two hours to complete before the result is communicated back to the manufacturing team. Thus, the following steps all contributed to the overall time for this IPC: cooling the reactor, sampling the reactor, transferring the sample to the QC lab, preparation of GC instrument and analysis of system suitability solutions, analyzing the sample, reviewing the data, reporting the results, and re-establishing the reactor temperature.
The ETG identified this IPC as being suitable for Raman analysis, as both of the solvents (dichloromethane [DCM] and acetone) generate significant and distinct responses in the Raman spectrum. A two-part plan was devised with the local analytical group. This plan was to initially develop and validate an at-line Raman method for the solvent exchange analysis as an equivalent alternative to the GC analysis and then subsequently introduce an equivalent, in-line Raman method. Once the team had demonstrated the feasibility of the at-line method, the second part of the plan, an in-line approach, was implemented. The rationale for the in-line analysis was to further improve process throughput, as the at-line Raman analysis still required that the reactor be cooled before sampling. An in-line analysis was developed using a Raman probe (Pilot E, Kaiser Optical Systems) that was placed directly in the reactor. The results were exported directly to a distributed control system (DCS) in the plant, realizing additional time savings through the elimination of the cooling and sampling steps.
In addition, the team identified an opportunity to enhance the plant efficiency by using spectroscopy for the molarity determination of hydrochloric acid in methanol (HCl in MeOH), a key reagent used in the manufacture of one of the drug substance processes run on the site. The plant had been determining the molarity using potentiometric titration, and the testing was required for both QC release testing of the reagent as well as an IPC test during batch processing. Despite the simplicity of titration testing, it was a time-consuming test that took a number of hours to complete because solutions needed to be prepared and standardized prior to sample analysis. FT-NIR was identified as an appropriate spectroscopic technique for the development of an at-line method. A method was developed and validated and then introduced as an equivalent alternative to the titration method, achieving greater than ten-fold reduction in sample turnaround time, as described in case study 2.
As described in the previous section, GC analysis for the solvent exchange step in the manufacture of a drug substance was being used to perform the IPC test. The total analysis time in the QC laboratory typically took approximately four hours to complete, including instrument setup, standard and sample preparation, analysis of system suitability, working standard, blank and reaction completion sample solutions, processing of the relevant data using chromatography data software (Empower, Waters), and the documentation review and approval. Because both solvents (DCM and acetone) possess strong Raman responses with unique and characteristic bands, Raman was a suitable spectroscopic technique for monitoring the solvent exchange.
At-line Raman analysis. Feasibility trials were performed using an analyzer (RXN2 Raman-785 nm, Kaiser Optical System) equipped with a HoloLab Analytical Sample Compartment (HLSC, Kaiser Optical System). Sample and standard solutions were analyzed in glass cuvettes. The absence of interfering fluorescence or other matrix effects was confirmed using process sample solutions.
A multivariate analysis model was developed that employed the ratio of the DCM peak response divided by the sum of DCM and acetone peak responses. Based on this simple model, a linear curve was established, bracketing the IPC specification for the solvent exchange, and was applied to the reaction samples.
Validation. Validation was successfully performed following ICH Q2(R) guidelines (7) and using the GC method as the primary reference method. Validation tests performed included specificity, linearity, limit of detection, precision, and accuracy. An equivalency protocol, in which process samples were analyzed by both the GC and Raman methods and the results from both data sets were compared against each other using predefined acceptance criteria, was also successfully performed. The Raman method was then introduced into the QC laboratory as an equivalent alternative to the GC method. Appropriate training and ongoing technical support were provided to the IPC chemists to ensure the Raman analysis was effectively introduced into the laboratory. The relevant regulatory filings were updated to include the application of the Raman analysis as an equivalent alternative to the GC analysis, thereby enabling use of the Raman analysis for commercial release.
The introduction of the at-line Raman method into the QC laboratory was successful, with QC chemists quickly understanding and appreciating the benefits of this mode of analysis. Key factors in the successful introduction were focused and concise documentation (including test methods, work instructions, etc.), a thorough and comprehensive training program, and the straightforward execution of the analysis. The sample analysis involved the placement of the sample in the HLSC and running the method on the RXN2 analyzer. Sample analysis time for the Raman analysis was 15 minutes compared with 240 minutes for the GC analysis, thereby enabling a significant reduction in result turnaround time using the Raman analysis (see Figure 1).
Model maintenance. It is important to demonstrate the continuing validity and accuracy of the chemometric model used in the spectroscopic method at regular time periods throughout the lifecycle of the method. This maintenance is necessary to account for the following: potential changes in vendors (which may utilize alternative synthetic routes for process reagents and solvents), instrument/model drift over time, and changes in the process manufacturing route. Validity is typically achieved by applying a change-control protocol and a model maintenance program to the chemometric model. Model maintenance for this IPC method involves repeating selected validation tests (e.g., specificity, accuracy, and precision) periodically, using the GC method as the primary reference method. The activities are documented in a protocol that is included in the maintenance report. Maintenance is performed annually or following any significant changes to the manufacturing process or raw material supply that are prompted by change-control actions.
In-line analysis.The introduction of the at-line Raman method resulted in reduced sample analysis times, reduced consumables for analysis (solvents, glassware), and increased sample throughput in the QC laboratory. As a result, the team assessed the feasibility of introducing an in-line application for the process to achieve even further savings by eliminating the need for cooling the reactor and sampling the reaction. Based on the high commercial volumes and the need to run frequent manufacturing campaigns, it was identified as an opportunity to save significant plant cycle time with a positive return on investment. The proposed in-line solution would involve the installation of a Raman probe (Pilot E, Kaiser Optical Systems) in the reactor, which would allow the reaction to be sampled directly in the reactor and eliminate the need to cool it. In addition, the processed IPC result would be automatically transferred to the DCS as part of the batch record. A cross-functional team comprised of representatives from manufacturing, engineering, analytical, information technology, and quality was assembled to perform a failure-modes effect analysis on the process step. Areas that were analyzed included in-line monitoring infrastructure requirements, mode of result generation and results reporting into the DCS, qualification and validation requirements, and equivalency/comparability requirements for the in-line analyzer.
The in-line application included developing an equivalent analysis model for an ATEX-rated Raman analyzer (RXN3-785, Kaiser Optical Systems) and acquisition of Raman spectra from the reactor vessel via a Raman probe (Pilot E, Kaiser Optical Systems) connected to the analyzer using fiber optic cables.
Equivalency between the at-line and in-line models was demonstrated using an equivalency protocol based on the data generated from the at-line and in-line models for in-process samples from the same reaction. Software (SynTQ Lite, Optimal Industrial Automation) was applied to the analyzer to provide a 21 Code of Federal Regulations (CFR) Part 11-compliant operating platform. Results generated were automatically exported to the DCS, which enabled real-time decisions to be made regarding progression of the manufacturing process. This installation eliminated the requirement to cool down the reactor, remove a sample, and perform an at-line analysis in the IPC laboratory, thereby generating even greater manufacturing cycle time gains.
Process knowledge obtained by observing real-time Raman trends during the solvent-exchange step resulted in a temperature-control step being added to the manufacturing batch record to ensure the product remained in solution, which further improved batch throughput. The knowledge was obtained through investigating irregular DCM concentration profiles during the solvent-exchange step using the in-line Raman probe. Negative concentration results were being reported, and upon review, it was noted that the raw Raman spectra were atypical for the negative concentration results. At-line analysis of the reactor supernatant displayed typical concentration results for DCM. The irregular profiles were typically generated in the early morning during the winter/spring season. The process solvent (acetone) was stored in an outside tank and was introduced into the reactor through pipework that was exposed to the outside elements. There was no temperature control of the reactor lagging jacket. Following a thorough review of the parameters of the process (e.g., time of year, external tank, and bulk process solvent being added in large volumes), it was hypothesized that the bulk acetone was being added at a sufficiently low temperature to cause the product to precipitate out of solution, which impacted the Raman scattering effect and generated the negative concentration values. A corrective measure introduced to counteract this effect was to introduce a temperature control of not less than 18 °C to the reactor lagging jacket. Following the introduction, the irregular DCM concentration profiles were no longer observed, which improved batch throughput.
A second opportunity identified to leverage spectroscopic-based methods to enhance the efficiency of the manufacturing plant and QC laboratory was the analysis of critical reagents and solutions. All reagents that are used in the commercial manufacturing process require release testing. In addition, many solutions that are prepared from these reagents will typically require an in-process release test before they can be used on the plant floor. The team identified the reagent HCl in MeOH as an application that might be suitable for analyzing using a spectroscopy-based alternative method. Because solutions of HCl in MeOH are hygroscopic and readily degrade on exposure to air, a rapid and accurate method was required to ensure that the correct concentration of reagent was being added to the reaction for each batch. The regulatory filed process called for the concentration of solutions of this reagent to be determined using simple acid/base titration. Despite the simplicity of this analytical technique, the analysis typically required over six hours from start to finish to generate and approve a result. This length of time was due to the numerous steps involved, including gathering the necessary glassware, solvents, and reagents; preparing and standardizing the various solutions; analyzing the sample; calculating the result manually; and reviewing and approving the result. The in-process analysis of this reagent solution had been identified as a process bottleneck, and the team assessed the option of introducing an equivalent spectroscopic method of analysis that could generate a result in a more expeditious manner. Based on initial feasibility studies including Raman, FT-IR, and FT-NIR, FT-NIR spectroscopy was identified as an appropriate technique for analyzing commercially sourced solutions of HCl in MeOH. The rationale for the selection of FT-NIR included sensitivity and selectivity for the compound of interest, ability to generate quantitative models, and availability of identical instrument models at both sites.
Results were generated using an analyzer (Antaris II FT-NIR, Thermo Scientific) in the transmission mode. The molarity of the reagent was determined using a partial least-squares chemometric model. The resulting FT-NIR method was capable of generating sample results in only two minutes. This short analysis time was enabled by embedding the chemometric model into the method, requiring only a single sample scan be acquired to generate a result. The analytical team at the BMS Ireland commercial manufacturing site had purchased an identical instrument to the one used by the ETG in the United States as part of the collaboration between the two groups. It had been previously recognized that alignment of both hardware and software components of the instrumentation at both sites would enable more effective knowledge transfer and troubleshooting/optimization activities, as well as enhance technology transfer of analytical methods.
Method transfer. Transfer of the FT-NIR method to the manufacturing site was conducted following the co-validation mode of technology transfer as defined by United States Pharmacopeia<1224> (8). Validation tests performed per ICH Q2 (R1) guidelines including specificity, linearity, repeatability, accuracy, and limit of detection/limit of quantitation (7). Acid/base titration analysis was used as the primary reference method during the validation. A comparability protocol was also successfully completed, in which 10 different lots of HCl in MeOH were analyzed using both the primary titration method and the secondary FT-NIR method and the results generated compared against predetermined acceptance criteria. Upon conclusion of the co-validation and comparability protocol testing, the results were summarized, and a proposal was submitted to the BMS Ireland site quality assurance function to introduce the FT-NIR method as an alternative equivalent to the titration method. The proposal was accepted, and the necessary activities to introduce the method, including raising a change control action, issuing of the test method report, and training the QC and IPC chemists were performed.
The acceptance of the introduction of the FT-NIR method has been uniformly positive from the process and analytical team members. Analysis is straightforward: the analyst decants the sample solution into a 2-mL vial, places the vial in the transmission cell of the spectrometer, and selects the appropriate workflow. A result is automatically generated by the instrument within two minutes. The ease of use and rapid result generation is well suited for the in-process control environment because it enables a result to be provided back to the process chemists within minutes of sample submission. Using the previous titration method, the processing team could be waiting hours for results, resulting in significant plant idle time.
Model maintenance. As with the Raman model detailed in case study 1, model maintenance is performed by repeating the validation tests using the primary titration method on an annual basis. If the site change-control management system captures any changes to the reagent supply parameters, instrument operation, or drug-substance manufacturing description that could impact the accuracy and validity of the partial least-squares model, model maintenance is triggered.
The introduction of the FT-NIR method in the commercial setting was successful. Result turnaround times were more than 10 times quicker than with the titration method, which was particularly beneficial to the in-process control work stream because it simplified analysis and facilitated improved manufacturing throughput times for this process, while at the same time freeing up analyst time in the QC laboratory to work on other high priority issues. As a result of the benefits and efficiencies gained through the introduction of the FT-NIR method for HCl in MeOH, the site identified three additional reagent concentration IPC methods that were creating bottlenecks in the plant workflows. Alternative, equivalent FT-NIR methods have subsequently been developed and introduced into the QC laboratory, resulting in faster turnaround times, simplified sample analyses, and a reduction of the resource demands in the laboratory.
The adoption of spectroscopic-based methods can improve the efficiency of analytical operations both within the plant environment (i.e., in IPC) and the QC laboratory. The two case studies highlight the time savings and analytical throughput increases obtained by introducing Raman spectroscopy as an alternative equivalent method to GC for solvent exchange monitoring and FT-NIR spectroscopy as an alternative equivalent to titration analysis for process reagent analysis.
In the Raman spectroscopy case study, significant efficiencies were obtained using both in-line and at-line applications. This example highlights an effective strategy for the introduction of spectroscopic technologies to a laboratory/manufacturing site. Initially introducing the at-line application to the site enabled the staff and management to gain a fuller understanding and appreciation of the advantages of the technology with a modest investment of time and effort. The subsequent introduction of the in-line application was achieved with strong support of management due to the prior experience with the at-line application.
The ease of use and ruggedness of the at-line applications facilitated enthusiastic uptake and ownership of the technologies by the laboratory chemists. At-line spectroscopic applications can facilitate improved analytical performance while minimizing the need for large resource investments, infrastructure, and maintenance activities associated with in-line/PAT applications. In addition, the at-line applications generated significant analytical operation efficiencies through improved sample throughput; reduction in analysis time, laboratory errors, and laboratory waste; increased laboratory capability; versatile analysis; and the capability to automate and network.
The authors wish to thank the various project team members in the US and Ireland that participated in discussions and/or collaborated in the development of these applications. In addition, they would like to thank the technical specialists at Kaiser Optical Systems Ltd, Optimal Industrial Automation Ltd., and Thermo Scientific Ltd., who facilitated the introduction of the spectroscopic instrumentation and software into the BMS manufacturing site in Swords, Ireland.
1. FDA Safety and Innovation Act (FDASIA) Section 902, 126 STAT. 993, Public Law (July 2012), pp. 112–144.
2. FDA, Guidance for Industry, Process Validation: General Principles and Practices (Rockville, MD, 2011). 3. ICH, Q8 (R2) Pharmaceutical Development (ICH, 2009).
4. ICH, Q9 Quality Risk Management (ICH, 2005).
5. ICH, Q10Pharmaceutical Quality System(ICH, 2008).
6. ICH, Q11Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (ICH, 2012).
7. ICH, Q2 (R1)Validation of Analytical Procedures: Text and Methodology(ICH, 1997).
8. USP, General Chapter <1224> “Transfer of Analytical Procedures”, USP 39-NF 34, pp.1638.
Vol. 43, No. 2
When referring to this article, please cite it as J. Wasylyk, M. Huang, B. Wethman, and K. O'Connor, "Spectroscopy Facilitates Lean Analysis," Pharmaceutical Technology 43 (2) 2019.
John Wasylyk* is senior principal scientist, email@example.com; Ming Huang is senior research investigator I; and Bob Wethman is senior research scientist II, all at Bristol-Myers Squibb, USA; Kieran O’Connor* is Analytical Science and Technology senior chemist at SK biotek, Ireland, firstname.lastname@example.org.
* To whom correspondence should be directed.